The competition authority issues its decision on the merger of Mehiläinen and Docrates Cancer Center
On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....
Read moreMon–Thu 8–18, Fri 8–16
Stereotactic body radiation therapy (SBRT) is well suited for the palliative treatment of metastases in the brain, liver, lungs and sometimes also in the bones.
Hypofractionated stereotactic radiotherapy effectively destroys local metastases. Radiotherapy is often given for metastases after chemotherapy to stabilise the disease. In this way, the disease can be controlled without further chemotherapy.
Oncologists in Finland have long been using hypofractionated stereotactic radiotherapy with great success. In the treatment of metastases, the patient may be given 1 to 5 hypofractionated high-dose radiotherapy doses depending on the size, location and previous treatment of the metastases.
SBRT is used for the treatment of urological and gynaecological cancers, lung, intestinal, liver and breast cancer, and for the treatment of metastases of other cancers. In certain cases, SBRT can also be used as primary treatment for cancer.
On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....
Read more
Breast cancer is a serious disease that requires individual care and expertise. As part of cancer treatment, the patient may...
Docrates treats metastatic colorectal cancer in a personalised way, and its treatment recommendations are based on the latest research and...
Cancer is a rapidly evolving medical specialty. Docrates publishes the latest news about cancer treatment, diagnostics and research a number...
Contact us!
Mon-Thu 8:00-18:00, Fri 8:00-16:00